These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 39101448)

  • 1. Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.
    Nemunaitis J; Stanbery L; Walter A; Wallraven G; Nemunaitis A; Horvath S; Bognar E; Rao D; Engle S; Brun S; Ghisoli M; Rocconi RP; Monk BJ; Coleman RL
    Future Oncol; 2024; 20(29):2149-2164. PubMed ID: 39101448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
    Rocconi RP; Stanbery L; Tang M; Madeira da Silva L; Walter A; Monk BJ; Herzog TJ; Coleman RL; Manning L; Wallraven G; Horvath S; Bognar E; Senzer N; Brun S; Nemunaitis J
    Commun Med (Lond); 2022; 2():106. PubMed ID: 36051466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
    Oh J; Barve M; Matthews CM; Koon EC; Heffernan TP; Fine B; Grosen E; Bergman MK; Fleming EL; DeMars LR; West L; Spitz DL; Goodman H; Hancock KC; Wallraven G; Kumar P; Bognar E; Manning L; Pappen BO; Adams N; Senzer N; Nemunaitis J
    Gynecol Oncol; 2016 Dec; 143(3):504-510. PubMed ID: 27678295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.
    Ghisoli M; Rutledge M; Stephens PJ; Mennel R; Barve M; Manley M; Oliai BR; Murphy KM; Manning L; Gutierrez B; Rangadass P; Walker A; Wang Z; Rao D; Adams N; Wallraven G; Senzer N; Nemunaitis J
    J Pediatr Hematol Oncol; 2017 May; 39(4):e183-e186. PubMed ID: 28338569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.
    Barve M; Aaron P; Manning L; Bognar E; Wallraven G; Horvath S; Stanbery L; Nemunaitis J
    Clin Med Insights Oncol; 2022; 16():11795549221110501. PubMed ID: 35957960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
    Rocconi RP; Grosen EA; Ghamande SA; Chan JK; Barve MA; Oh J; Tewari D; Morris PC; Stevens EE; Bottsford-Miller JN; Tang M; Aaron P; Stanbery L; Horvath S; Wallraven G; Bognar E; Manning L; Nemunaitis J; Shanahan D; Slomovitz BM; Herzog TJ; Monk BJ; Coleman RL
    Lancet Oncol; 2020 Dec; 21(12):1661-1672. PubMed ID: 33271095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
    Rocconi RP; Stevens EE; Bottsford-Miller JN; Ghamande SA; Elder J; DeMars LL; Munkarah A; Aaron P; Stanbery L; Wallraven G; Bognar E; Manley M; Horvath S; Manning L; Walter A; Galanis E; Herzog T; Monk BJ; Coleman RL; Nemunaitis J
    Cancer Gene Ther; 2022 Mar; 29(3-4):369-382. PubMed ID: 33753870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
    Walter A; Rocconi RP; Monk BJ; Herzog TJ; Manning L; Bognar E; Wallraven G; Aaron P; Horvath S; Tang M; Stanbery L; Coleman RL; Nemunaitis J
    Gynecol Oncol; 2021 Dec; 163(3):459-464. PubMed ID: 34702567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Zhang Y; Zhang L; Zhao Y; Wang S; Feng L
    Front Oncol; 2022; 12():945867. PubMed ID: 36338747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.
    Senzer N; Barve M; Kuhn J; Melnyk A; Beitsch P; Lazar M; Lifshitz S; Magee M; Oh J; Mill SW; Bedell C; Higgs C; Kumar P; Yu Y; Norvell F; Phalon C; Taquet N; Rao DD; Wang Z; Jay CM; Pappen BO; Wallraven G; Brunicardi FC; Shanahan DM; Maples PB; Nemunaitis J
    Mol Ther; 2012 Mar; 20(3):679-86. PubMed ID: 22186789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
    Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.
    Ghisoli M; Barve M; Mennel R; Lenarsky C; Horvath S; Wallraven G; Pappen BO; Whiting S; Rao D; Senzer N; Nemunaitis J
    Mol Ther; 2016 Aug; 24(8):1478-83. PubMed ID: 27109631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoantigen: A New Breakthrough in Tumor Immunotherapy.
    Zhang Z; Lu M; Qin Y; Gao W; Tao L; Su W; Zhong J
    Front Immunol; 2021; 12():672356. PubMed ID: 33936118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response.
    Nemunaitis J; Stanbery L; Willoughby D; Bognar E; Brun S; Walter A; Monk BJ; Rocconi RP; Choucair K; Coleman RL
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6.
    Barve V; Adams N; Stanbery L; Manning L; Horvath S; Wallraven G; Bognar E; Barve M; Nemunaitis J
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors.
    Vernet R; Fernandez E; Migliorini D; Ancrenaz V; Charrier E; Belkouch MC; Von Rohr O; Urwyler M; De Vito C; Renaux J; Villard J; Rubin O; Grogg J; Mach N
    Cancer Res Commun; 2024 Aug; 4(8):2089-2100. PubMed ID: 39041242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and clinical development of neoantigen vaccines.
    Li L; Goedegebuure SP; Gillanders WE
    Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
    Rocconi RP; Monk BJ; Walter A; Herzog TJ; Galanis E; Manning L; Bognar E; Wallraven G; Stanbery L; Aaron P; Senzer N; Coleman RL; Nemunaitis J
    Gynecol Oncol; 2021 Jun; 161(3):676-680. PubMed ID: 33715892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.